Fetal toxicity of angiotensin-II-receptor inhibitors. Case report;Toxicité fœtale des antagonistes des récepteurs de l'angiotensine II. À propos d'un cas

Gynecologie Obstetrique et Fertilite

Volumn 35, Issue 6, 2007, Pages 556-560

  Roger, N ^a   Popovic, I ^a   Madelenat, P ^a   Mahieu Caputo, D ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Angiotensin II receptor inhibitors; Fetopathy; Oligohydramnios

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; LABETALOL; METHYLDOPA; NICARDIPINE; VALSARTAN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL STUDY; EMBRYOTOXICITY; EXPERIMENTAL STUDY; FEMALE; FETUS; FETUS DISEASE; HUMAN; KIDNEY FAILURE; OLIGURIA; POTTER SYNDROME; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRENATAL EXPOSURE; CHEMICALLY INDUCED DISORDER; HYPERTENSION; NEWBORN; PREGNANCY COMPLICATION; PREGNANCY OUTCOME;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; INFANT, NEWBORN; KIDNEY FAILURE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; TETRAZOLES; VALINE;

EID: 34250310864     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2007.03.015     Document Type: Article

References (14)

1. Hilgers K.F., Norwood V.F., and Gomez R.A. Angiotensin's role in renal development. Semin. Nephrol. 17 5 (1997) 492-501
2. Guron G., and Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J. Hypertens. 18 2 (2000) 123-137
3. Saji H., Yamanaka M., Hagiwara A., and Ijiri R. Losartan and fetal toxic effects. Lancet 357 9253 (2001) 363
4. Lambot M.A., Vermeylen D., and Noel J.C. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357 9268 (2001) 1619-1620
5. Martinovic J., Benachi A., Laurent N., Daikha-Dahmane F., and Gubler M.C. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 358 9277 (2001) 241-242
6. Hinsberger A., Wingen A.-M., and Hoyer P.F. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357 9268 (2001) 1620
7. Pietrement C., Malot L., Santerne B., Roussel B., Motte J., and Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J. Perinatol. 23 3 (2003) 254-255
8. Briggs G.G., and Nageotte M.P. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann. Pharmacother. 35 7-8 (2001) 859-861
9. Serreau R., Luton D., Macher M.A., Delezoide A.L., Garel C., and Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases (2005), BJOG
10. Bos-Thompson M.A., Hillaire-Buys D., Muller F., Dechaud H., Mazurier E., Boulot P., et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Ann. Pharmacother. 39 1 (2005) 157-161 (Epub 2004 Dec 8)
11. Mastrobattista J.M. Angiotensin converting enzyme inhibitors in pregnancy. Semin. Perinatol. 21 2 (1997) 124-134
12. Pryde P.G., Sedman A.B., Nugent C.E., and Barr Jr. M. Angiotensin-converting enzyme inhibitor fetopathy. J. Am. Soc. Nephrol. 3 9 (1993) 1575-1582
13. Mahieu-Caputo D., Dommergues M., Delezoide A.L., Lacoste M., Cai Y., Narcy F., et al. Twin-to-twin transfusion syndrome. Am. J. Pathol. 156 (2000) 629-636
14. Chung N.A., Lip G.Y., Beevers M., and Beevers D.G. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357 9268 (2001) 1620-1621